Class I antiarrhythmic drugs inhibit the sodium channel by binding to a drug receptor associated with the channel. In this report we show that in vivo administration of the class I antiarrhythmic drug mexiletine to rats induces sodium channel upregulation in isolated cardiac myocytes. The number of sodium channels was assessed with a radioligand assay using the sodium channel-specific toxin Invest. 1991. 88:375-378.)
Introduction
The pharmacologic treatment of cardiac arrhythmias is frequently limited by resistance to therapy with Class I antiarrhythmic drugs. Class I drugs block the cardiac sodium channel by binding to a receptor associated with the channel. We have previously reported that some patients who respond to intravenous Class I drugs subsequently develop drug resistance during chronic oral treatment (1) . One possible explanation for this finding is that drug therapy induces drug resistance. We hypothesized that a mechanism of resistance to Class I drugs might be a drug-induced time-dependent increase in the number of cardiac sodium channels.
Accordingly, we determined whether treatment of rats for 1-6 d with the Class I antiarrhythmic drug mexiletine induced an increase in the number of cardiac sodium channels. The Class I drug mexiletine (2) was selected for administration to rats because it has a long biological half-life, it is water soluble and therefore should be easily washed out from isolated cardiac myocytes, and it is electrophysiologically similar to the prototypic Class I drug lidocaine. The number of sodium channels was assessed with a conventional radioligand assay (3) using the sodium channel-specific toxin Quebec) by collagenase dispersion using the method ofKryski et al. (4) . This method routinely yielded -60 mg (dry wt) of myocytes, which corresponds to 1.2 X 107 cells (4, 5) . The cells were 85-90% viable rod-shaped cells that excluded trypan blue and were tolerant of 1 mM calcium.
[3H]BTXB equilibrium binding Equilibrium binding assays were performed as described previously (3) . Myocytes (6 x I0O cells/assay) in 50 Ml ofincubation buffer (MEM with 50 MM CaCl2 and 1% dialyzed BSA) were incubated with 1.3 MM sea anemone toxin (ATX), 0.13 mM tetrodotoxin (TTX), and various concentrations of [3H]BTXB for 55 min at 370C.
TTX was added to prevent depolarization induced by sodium influx; without TTX, no specific binding is observed (6, 7) . Assays were done in parallel with tubes containing 0.4 mM aconitine to define the nonspecific binding. Reactions were stopped by adding 10 ml ofKrebsHenseleit BSA buffer (127 mM NaCl, 2.33 mM KCl, 1.3 mM KH2PO4, 1.23 mM MgSO4, 25 mM NaHCO3, 10 mM glucose, 50,uM CaCl2, and 1% BSA) that was equilibrated with 95% 02-5% CO2, incubated at 37°C for 1 min, filtered through a GF/C 24-mm filter (Whatman Laboratory Products, Inc., Clifton, NJ), and washed four times with 5 ml of rinse buffer (25 mM Tris HCl, pH7.4, 130 mM NaCl, 5.5 mM glucose, and 50 MM CaC12). The filters were dried and counted in Econofluor scintillation fluid (New England Nuclear, Mississauga, Ontario). The retained radioactivity represents [3H]BTXB bound to myocytes.
The rationale for the incubation and the filtration conditions have previously been described (7 (2) . After 3 d of in vivo treatment pairs of placebo-and mexiletine-treated rats were killed and cardiac myocytes prepared for radioligand studies.
Time-dependence of channel expression. Pairs of rats were randomly assigned to receive placebo or mexiletine (50 mg/kg per d) daily and were killed after 0, 1, 2, 3, 4, and 6 d oftreatment for preparation of myocytes for radioligand analysis.
Time-dependence of recovery to baseline. Pairs of rats were randomly assigned to placebo or mexiletine (50 mg/kg perd) treatment for 3 d, after which treatment was discontinued. Pairs of rats were killed 0, 2, 4,5,6, and 12 d after treatment was discontinued and myocytes were prepared for radioligand studies.
Study design and statistical analysis
To minimize day-to-day variability in rats and drug and toxin preparations, all experiments were done in a paired fashion. Pairs of weightmatched adult male Sprague-Dawley rats (200-250 g) were randomly assigned to receive either subcutaneous placebo or mexiletine. This paired approach was used in all phases of this investigation including assessment ofdose-dependence, time-dependence, time-dependence of recovery of channel number, and the effects of chronic therapy on the characteristics of in vitro ligand/receptor interactions. Data are presented as mean± 1 SD. Analysis ofvariance was used to assess the significance of the dose and time-dependent changes in sodium channel number.
Measurement of ouabain-sensitive sodium, potassiumactivated ATPase
Freshly excised rat hearts were each minced in 2.5 ml solution 1(127 mM KCl, 10 mM Hepes-Tris pH 7.2, 1 mM PMSF, 1 mM iodoacetamide, 1 mM EGTA, 0.1 ug/ml pepstatin) and homogenized with a Polytron (45-s duration at full power; Brinkman Instruments [Canada] Ltd., Rexdale, Ontario). The homogenate was centrifuged at 600 g at 4VC for 10 min and the resulting pellet was then homogenized in 5 ml solution I. After centrifugation at 4VC for 10 min at 10,000 gthe resultant pellet was then homogenized in 5 ml solution 11(300 mM sucrose, 10 mM Hepes-Tris pH 7.2). This suspension was centrifuged twice at 4°C at 7,000 g for 20 min and the supernatant fluid was then centrifuged at 275,000 g for 1 h at 4°C. The resulting pellet was then assayed for both protein concentration and ouabain-sensitive sodium, potassium-activated ATPase by the method ofMonahan and Jones (8) . Each heart was processed separately.
Analysis ofprotein and mexiletine
Protein concentration was determined by the Lowry method (9). To assess the concentration of mexiletine produced during subcutaneous treatment, rats were killed 2 h and 24 h after its administration. The chest was opened, the heart punctured, and a 2-ml blood sample removed. Serum concentrations of mexiletine were assayed using a high performance chromatographic method (10 each dose. The effect of mexiletine treatment on the number of binding sites was highly significant (P < 0.001) whereas mexiletine had no significant effect on the affinity in vitro of [3HJ-BTXB for the sodium channel. The paired design ofthe experiments allowed expression of the data as the ratio of B,.,j of drug-treated rats to the B,,,, of placebo-treated rats. This B., ratio also increased progressively and significantly with increasing doses of mexiletine (P < 0.001; Table I ). The possibilities that these changes in sodium channel number might in fact be due to spurious changes in cell recovery or in nonspecific changes in membrane-bound proteins were assessed by three methods. First, sodium channel numbers when expressed as fmol/103 viable, rod-shaped cells increased significantly after treatment with mexiletine (Table I) . Second, sodium channel numbers when expressed as fmol/mg protein also increased after treatment with mexiletine. For example, control rats had 147±22 fmol sodium channels per mg protein, while rats Time-dependence of mexiletine effect on sodium channel number. The time-dependence of the effect of mexiletine on sodium channel number was assessed by preparing cardiac myocytes from paired rats randomly assigned to treatment with mexiletine (50 mg/kg per d) or placebo for 0-6 d. Fig. 2 shows the time-dependence ofincrease in the ratios-ofthe B, (Fig. 4 A) and from treated rats that had received 50 mg/kg per d of mexiletine for 3 d (Fig. 4 B) . The myocytes were incubated in vitro as in Fig. I in absence (.) or in presence (o) of 40MgM mexiletine and various concentrations of [3H]BTXB. Specifically-bound [3H]BTXB was determined as described in Fig. 1 . Linear regression best-fit values for the control myocytes (Fig. 4 A) (Fig. 4 B) (10) (0.1 ig/ml). By comparison, the serum concentrations ofmexiletine that are usually observed are 0.7-1.5 jig/ml.
Discussion
We have shown that chronic in vivo treatment of rats with mexiletine, a drug that blocks cardiac sodium channels, induced a significant increase in the number of cardiac sodium channels. Mexiletine increased sodium channel number by up to threefold in a dose-dependent fashion. This increase in sodium channel number reached a maximum value after 3 d of treatment. After discontinuation of chronic treatment sodium channel number declined to the baseline values within 12 d. These data suggest that the sodium channel is under physiologic regulation and that during chronic Class I antiarrhythmic drug treatment sodium channels may be increased. Mexiletine levels. The undetectably low levels of serum mexiletine suggest that either sodium channel regulation in rats is exquisitely sensitive to the drug, or that subcutaneous drug administration produces effects that might not be seen with intravenous or oral drug administration. While the latter explanation cannot be eliminated, it is noteworthy that all control rats received sham injections, and that another membranebound protein (ATPase) did not exhibit similar changes. Thus the changes in sodium channel number appear to reflect a sodium channel-specific response to serum mexiletine, albeit at low concentrations.
Mechanism of increase in sodium channels. How mexiletine induces this increase in vivo remains speculative, but previous work by others suggests that this effect is also seen in vitro with rat muscle sodium channels. Sherman and Catterall (1 1) showed that exposure of rat myotubes to bupivicaine or tetrodotoxin significantly increased the number of cell-surface tetrodotoxin-sensitive sodium channels. They hypothesized that the increase in channels was mediated by a decrease in intracellular calcium, in turn due to a decreased number of action potentials in cells that were otherwise electrically active.
The origin of the upregulated channels is also unclear. The nerve sodium channel undergoes a complex series ofmetabolic modifications between translation and eventual cell-surface expression ( 12, 13) and there is a large intracellular pool of inactive alpha subunits (14) . Furthermore, cAMP both inhibits (15) and downregulates (16) the cardiac sodium channel. The leisurely time-courses ofboth upregulation and return to baseline values in this report suggest that de novo synthesis and degradation of sodium channels are involved, although slow shuttling to and from an inactive intracellular pool (14) cannot be eliminated.
Clinical implications. This modulation of sodium channel number may have clinical relevance. We have previously reported that acute antiarrhythmic response to Class I drugs does not necessarily predict a similar favorable response during chronic oral therapy (1) . This discrepancy occurred even though plasma concentrations of Class I antiarrhythmic drug were equivalent during acute and chronic therapy. The discrepancy between acute and chronic therapy in vivo may be related to a number of potential factors including differences in pharmacodynamic penetrance ofmyocardium and time-dependent accumulation of active metabolites but these results raise the possibility that resistance to Class I antiarrhythmic drugs may be in part modulated by an increase in the number of cardiac sodium channels.
